LILLY GEMZAR SELLS $31.6 MIL. IN SIX MONTHS ON U.S. MARKET; PRINIVIL IS MERCK's "ACE" IN HOLE WITH 33% U.S. SALES JUMP; FOSAMAX SALES IN EXCESS OF $200 MIL. IN U.S.
Lilly's Gemzar generated $31.6 mil. in U.S. sales from its May launch for treatment of prostate cancer. Gemzar contributed worldwide sales of $61.9 mil. for 1996, of which $26.3 mil. was in the fourth quarter.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth